Skip to main content
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CTXR ISIN · US17322U2078 LEI · 5493005C10W36P4KQP40 US Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2017-07-24 Capital/Financing Update
Country US United States of America
Listing US CTXR

About Citius Pharmaceuticals, Inc.

https://www.citiuspharma.com/

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and commercializes critical care products. The company's diversified pipeline focuses on anti-infectives in adjunct cancer care, stem cell therapies, and prescription products. Its portfolio includes LYMPHIR™, an FDA-approved therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Key product candidates in development include Mino-Lok®, an antibiotic lock solution intended to treat patients with catheter-related bloodstream infections, and Halo-Lido, a topical formulation for the treatment of hemorrhoids. Additionally, the company is advancing a stem cell therapy platform for conditions such as acute respiratory distress syndrome (ARDS).

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2017
Capital/Financing Update Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding a Registration Statement on Form S-1. It requests acceleration of the effective date for the Registration Statement and discusses distribution of the Preliminary Prospectus. There is no financial data, report content, or detailed analysis present. The document is short (1609 characters) and serves as a regulatory communication related to a capital raising process. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2017-07-24 English
FORM S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A (Amendment No. 3) registration statement filed with the SEC under the Securities Act of 1933. It is a registration statement for a public offering of securities, including common stock and warrants. The document includes detailed information about the offering, risk factors, use of proceeds, market for common stock, capitalization, dilution, dividend policy, management discussion and analysis, business description, management, security ownership, underwriting, legal matters, and financial statements. This type of filing is related to capital raising activities and securities registration, not an annual report, earnings release, or other financial report. Therefore, it fits the category of Capital/Financing Update (CAP).
2017-07-21 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions that the company posted presentation materials on its website and that these materials are furnished as an exhibit to the Form 8-K. The document itself is short (2658 characters) and primarily serves to announce the availability of the presentation materials rather than containing the full presentation or detailed financial data. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full investor presentation or detailed financial report itself. It is not an Investor Presentation (IP) because the actual presentation is only referenced and attached as an exhibit, not included in full in the text. Therefore, the appropriate classification is RNS with high confidence.
2017-07-13 English
FORM S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A (Amendment No. 2) registration statement filed with the SEC under the Securities Act of 1933. It is a registration statement for a public offering of common stock and warrants by Citius Pharmaceuticals, Inc. The document includes detailed information about the offering, risk factors, use of proceeds, market for common stock, capitalization, dilution, dividend policy, management discussion and analysis, business description, management, security ownership, underwriting, legal matters, experts, and financial statements. This type of filing is a capital raising document used to register securities for sale to the public. It is not an annual report, earnings release, or any other type of report or announcement. It is specifically a registration statement related to capital raising and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-07-13 English
424B3
Capital/Financing Update Classification · 95% confidence The document is titled 'Prospectus Supplement No. 4' and references a Registration Statement No. 333-216030. It discusses updates and amendments to a previously filed prospectus, including details about a convertible promissory note and related agreements. The document is a supplement to a prospectus, which is a disclosure document related to securities offerings and financing activities. It is not a full financial report, earnings release, or management discussion. The content focuses on financing arrangements and securities offering details, which aligns with Capital/Financing Update filings. The document length is under 5,000 characters but contains substantive information about financing terms, not merely an announcement of a report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-07-05 English
FORM S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A registration statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the offering, risk factors, management discussion, financial statements, and other disclosures typical of a registration statement for an initial or follow-on public offering. This type of filing is related to capital raising activities and financing updates rather than annual reports, earnings releases, or other categories. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or certification.
2017-07-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.